Blockchain Registration Transaction Record

VolitionRx and Sysmex Collaborate to Optimize Nu.Q NETs Assay

VolitionRx partners with Sysmex to optimize Nu.Q NETs H3.1 assay for sepsis and NETosis diseases, targeting $3.8B market. Read more at BioMedWire.

VolitionRx and Sysmex Collaborate to Optimize Nu.Q NETs Assay

This collaboration matters because it accelerates the development of a diagnostic test that could improve early detection and monitoring of sepsis and other NETosis-related diseases, potentially saving lives and reducing healthcare costs. By leveraging Sysmex's global platform, Volition's technology could reach patients faster, addressing a $3.8 billion market opportunity and transforming patient outcomes.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x9424ea513f3a17824440890478a9157816a973b290b0ac22d085cf109e33abed
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintgainibdu-9cbfe7f6b435bc41d0117eb6aced9fa2